One of our Headlands Research colleagues previously discussed the scientific foundations of psychedelic medicine and the mechanisms that distinguish these compounds from conventional treatments in a blog post available on the website. Now, a series of regulatory developments in the U.S. signal that the field may be moving from a period of scientific revival into a more formal regulatory and clinical development phase. For individuals with treatment-resistant depression (TRD), post-traumatic stress disorder (PTSD), or substance use disorder (SUD), these compounds may offer meaningful and potentially even life-saving new options.
However, despite the recent enthusiasm around their promise, research into psychedelics has been limited, and few have entered late-stage trials for thorough evaluation of efficacy and safety. Therefore, questions remain about whether these treatments may help certain participants and do so safely, as well as how they will be delivered, accessed, and monitored in clinical care settings if approved. To better understand what this shift may mean, it's worth examining where the field stands today.
A changing regulatory landscape
As the healthcare and life sciences industry continues to grapple with intractable mental health conditions such as TRD and PTSD, prior findings of positive benefits of psychedelic therapies as well as anecdotal evidence from participants have maintained interest in the potential of these treatments to fill the gap. As a result, several biopharma companies have advanced clinical programs, and recent regulatory actions have renewed broader attention to psychedelic medicine development.
On April 18, 2026, U.S. President Trump issued an executive order aimed at “accelerating medical treatments for serious illness.” The executive order called for $50 million in funding to “advance psychedelic drugs for serious mental illnesses,” Commissioner’s National Priority Vouchers (CNPVs) for “psychedelic drugs that have received a Breakthrough Therapy designation and are in accordance with the criteria of the National Priority Voucher Program,” and the establishment of a “pathway for eligible participants to access psychedelic drugs…, including any necessary Schedule I handling authorizations for treating physicians and researchers.”
The CNPVs shorten approval review timelines from 6 months or more to 1-2 months from the date of application and enable improved communication with the FDA. Following the executive order announcement, the FDA issued three, including one for synthetic psilocybin for TRD and another for methylone for the treatment of PTSD. An NDA was already planned for Q4 2026 for the psilocybin therapeutic, based on findings from two Phase III trials showing statistically significant results and a clinically meaningful effect for TRD.
The executive order also specifically referenced ibogaine, permitting researchers to study it for the first time in the U.S. An Investigational New Drug (IND) application was accepted by the U.S. FDA the following week for an oral noribogaine therapy for alcohol use disorder.
Where the evidence stands today
As we discussed in our previous blog post, TRD, PTSD, and SUD have high unmet need, can be profoundly disabling, and have large groups of participants who do not respond adequately to current treatments. Psychedelic compounds may offer a fundamentally different approach: emerging evidence suggests they have larger effect sizes than currently available therapies, with the potential to induce neuroplasticity and produce structural and functional brain changes that may lead to durable therapeutic effects.
For TRD, even a meaningful response would matter for the subset of participants who have spent years trying evidence-based treatments without recovering their function. The most recently reported Phase III results of psilocybin demonstrate the possibility of a rapid antidepressant effect and even remission after one or two supervised dosing sessions, particularly when paired with psychological support. For some, this effect lasted for the 26 weeks of the study, with ongoing monitoring still underway.
In PTSD, where the aim is to do more than merely reduce symptoms, entactogens are a promising approach for their potential ability to influence self-perception, social interaction, and fear memory without the hallucinogenic properties of classical psychedelics such as psilocybin. Within the entactogen class, studies of MDMA have shown benefits for helping the brain reprocess fear, memory, safety, and meaning.
Although it has been studied less than MDMA, methylone’s mechanism of action is considered similar to that of MDMA but with less potent effects at all three of the targeted monoamine transporters: dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin (5-HT) transporter (SERT). It also appears to have greater specificity and fewer off-target effects than MDMA, potentially enabling greater effects on empathy, emotional openness, fear extinction, and depressive symptoms.
For SUD, ibogaine and noribogaine-related compounds are compelling options. The small body of available evidence for these compounds suggests strong anti-addictive properties that reduce cravings for alcohol and drugs such as opioids and cocaine. In addition, they have produced significant improvements in PTSD for military veterans. However, serious safety concerns around cardiac risks and QTc prolongation still need to be resolved and will likely require close monitoring.
Other mental health conditions such as obsessive-compulsive, personality, eating, or adjustment disorders also have significant unmet treatment needs. Therefore, these are also of interest within the psychedelic therapeutic landscape but have received less focus in research to date.
Why the term "psychedelics" is too broad
The evidence presented above underscores an important distinction: the term “psychedelics” is too broad for clinical purposes because these compounds are not interchangeable. Psilocybin, methylone, MDMA, ketamine, and noribogaine differ significantly in mechanism, subjective experience, safety profile, and monitoring needs. These characteristics will also likely determine the most appropriate clinical applications.
Psilocybin is a classical psychedelic that produces hallucinogenic effects. Methylone is better characterized as an entactogen and neuroplastogen, influencing emotional processing and social connection without the hallucinogenic intensity of classical psychedelics. Noribogaine exhibits an extraordinarily complex, multi-target pharmacological profile (sometimes called “matrix pharmacology”) and raises a distinct set of safety and regulatory questions, particularly around cardiac monitoring. Understanding these differences is essential for appropriate participant selection, treatment design, and regulatory evaluation.
The science behind why setting and participant selection matter
Psychedelic compounds may not just suppress symptoms. Instead, they might temporarily increase the brain's capacity for change through neuroplasticity, network flexibility, fear-extinction learning, and psychological flexibility. One of the most significant recent discoveries is that these agents can reopen developmentally restricted critical periods of plasticity (specifically the social reward learning critical period) in the adult brain. This property may fundamentally explain both their durability and their context-dependence. It is as if the adult brain gains a temporary opportunity to relearn patterns that were established during early childhood development, but this time with different input.
This mechanistic insight is clinically important because it helps explain why set, setting, preparation, monitoring, and integration appear to be integral components of the treatment model rather than optional additions. If these compounds create a window in which therapy or environmental input has a greater effect, then what happens during and after that window may significantly influence outcomes.
What this means for research and clinical practice
The current state of the evidence for the efficacy, effectiveness, and safety of these compounds as well as the evolving understanding of their mechanisms of action have direct implications for how these treatments are further studied and delivered.
The research questions remain substantial (but not insurmountable), including:
- Who benefits most, and who should be excluded?
- How much psychological support is necessary?
- How durable are the effects, and what factors influence that durability?
- How should functional unblinding, which may inflate apparent efficacy, be managed in trials?
- How should suicidality and cardiovascular risk be monitored?
- How do these treatments perform in broader, more diverse, real-world populations?
The caution at this juncture is not to confuse biological novelty with clinical readiness. Trials must demonstrate not only that these treatments work but also that they can be delivered safely, ethically, and reproducibly. This requires controlled environments for testing acute effects as well as close monitoring for durability of response.
In practice, these are not ordinary prescription-pad treatments. If approved for clinical use, these therapies are likely to function as adjuncts to ongoing integrative psychotherapy and will require treatment pathways that promote careful screening, preparation, monitored administration, and follow-up.
The complexity of delivery raises an equally important question: who will actually be able to access these treatments? Limiting factors to equitable use include cost, clinic infrastructure, trained clinicians, monitoring requirements, payer coverage, session length, and participant suitability. In smaller communities or rural regions, access could be especially uneven, as has been demonstrated for esketamine nasal spray for participants with major depressive disorder that is challenging to treat or treatment-resistant. The healthcare field and public payers should work to ensure that these treatments, if approved, do not become available only to the most resourced participants, such as those who currently have the means to access psychedelic therapies through medical tourism.
However, public demand from participants and families living with these conditions could drive program implementation. Some early models of regulated access already exist in the U.S., such as psilocybin-assisted therapy in Oregon and healing centers in areas of Colorado, and these could be used as proof of concept for others. In addition, careful evaluation of the cost-benefit equation will be essential and should include the direct costs of delivering these treatments as well as potential reductions in the long-term burden and societal costs of depression, PTSD, addiction, and related disorders.
A measured, yet hopeful, path forward
The FDA's recent actions suggest that regulators are taking the field seriously — not by lowering the bar, but by creating a path for rigorous, well-controlled, carefully monitored development. For participants who have spent years trying standard medications and psychotherapies without adequate recovery, these treatments may offer something fundamentally different: the possibility of working through alternative pathways, including neuroplasticity, fear extinction, psychological flexibility, and changes in rigid brain-network patterns.
This is not a promise that a cure is around the corner but rather that serious science is being applied to compounds that may help where conventional treatments have sometimes been inadequate. Important questions about durability, dosing, relapse, participant selection, and the role of psychotherapy remain to be answered, but our hope is that we are moving toward a more mature phase of psychedelic and psychoplastogen research — one that is neither dismissive nor evangelical but one that offers participants both hope and rigor.
About the authors
Pieter Strauss, MD, MBChB, FRCPC, is a fellowship-trained psychiatrist and clinical trials investigator with decades of experience in clinical psychiatry, leadership, and wellness-focused care. He currently serves as a Principal Investigator at Headlands Okanagan Clinical Trials.
Dr. Strauss completed his medical degree and psychiatry residency at the University of the Free State in South Africa and is a Fellow of the Royal College of Physicians of Canada. His career includes long-standing community psychiatry practice, hospital-based care, and executive leadership as former Chief of the Department of Psychiatry at Abbotsford Regional Hospital. His research experience includes participation in Phase 3 clinical trials in psychiatry and neurology, with investigational therapies such as olanzapine, risperidone, and donepezil. He is trained in Good Clinical Practice and Health Canada Division 5 requirements and brings a participant-centered, ethically grounded approach to clinical research.
Beal Essink, MD, is a board-certified psychiatrist with extensive experience across both inpatient and outpatient settings and has a long-standing passion for clinical research. He has been a member of the Headlands Summit Research Network investigator team since September 2021. Dr. Essink has been conducting studies since 2003 and has served as an investigator on more than 250 clinical trials, contributing to advancements across a wide range of psychiatric and neurologic indications. Recognized for his leadership and dedication to the field, Dr. Essink brings a deep commitment to rigorous, participant-centered research and to advancing innovative therapies that improve lives.